Herbst R - Search Results

1

9:00-9:15. Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors.

Mullani N, Herbst R, Abbruzzese J, Charnsangavej C, Kim E, Tran H, Barron B, Lamki L, Gould K. Mullani N, et al. Among authors: herbst r. Clin Positron Imaging. 2000 Jul;3(4):151. doi: 10.1016/s1095-0397(00)00063-7. Clin Positron Imaging. 2000. PMID: 11150754

2

9:30-9:45. First Pass FDG Measured Blood Flow in Tumors: A Comparison with O-15 Labeled Water Measured Blood Flow.

Mullani N, Herbst R, Abbruzzese J, Barron B, Lamki L, Charnsangavej C, Kim E, Tran H, Jiwani A, Gould K. Mullani N, et al. Among authors: herbst r. Clin Positron Imaging. 2000 Jul;3(4):153. doi: 10.1016/s1095-0397(00)00065-0. Clin Positron Imaging. 2000. PMID: 11150756

3

Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin.

Herbst RS, Lee AT, Tran HT, Abbruzzese JL. Herbst RS, et al. Curr Oncol Rep. 2001 Mar;3(2):131-40. doi: 10.1007/s11912-001-0013-8. Curr Oncol Rep. 2001. PMID: 11177745

4

Epidermal growth factor receptor biology (IMC-C225).

Kim ES, Khuri FR, Herbst RS. Kim ES, et al. Among authors: herbst rs. Curr Opin Oncol. 2001 Nov;13(6):506-13. doi: 10.1097/00001622-200111000-00014. Curr Opin Oncol. 2001. PMID: 11673692 Review.

5

A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.

Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, Jung M, Hong WK, Herbst RS. Kim ES, et al. Among authors: herbst rs. Lung Cancer. 2001 Dec;34(3):427-32. doi: 10.1016/s0169-5002(01)00278-1. Lung Cancer. 2001. PMID: 11714540 Clinical Trial.

6

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.

Herbst RS, Kim ES, Harari PM. Herbst RS, et al. Expert Opin Biol Ther. 2001 Jul;1(4):719-32. doi: 10.1517/14712598.1.4.719. Expert Opin Biol Ther. 2001. PMID: 11727507 Review.

7

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.

Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Tseng JE, et al. Among authors: herbst rs. Cancer. 2001 Nov 1;92(9):2364-73. doi: 10.1002/1097-0142(20011101)92:9<2364::aid-cncr1584>3.0.co;2-p. Cancer. 2001. PMID: 11745292 Clinical Trial.

8

Novel therapeutics for head and neck cancer.

Kim ES, Kies M, Herbst RS. Kim ES, et al. Curr Opin Oncol. 2002 May;14(3):334-42. doi: 10.1097/00001622-200205000-00014. Curr Opin Oncol. 2002. PMID: 11981281 Review.

9

Angiogenesis inhibitors in lung cancer.

Kim ES, Herbst RS. Kim ES, et al. Curr Oncol Rep. 2002 Jul;4(4):325-33. doi: 10.1007/s11912-002-0008-0. Curr Oncol Rep. 2002. PMID: 12044242 Review.

10

Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial.

Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Daniel Ayers G, Herbst RS, Abbruzzese JL. Pentz RD, et al. J Clin Oncol. 2002 Sep 15;20(18):3785-91. doi: 10.1200/JCO.2002.04.084. J Clin Oncol. 2002. PMID: 12228198

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

901 results

Search Page